Clinical trials: Lipid Lowering, Vascular Inflammation
Hypercholesterolemia, Hypercholesterolemia, Familial
PET Imaging of Inflammation and Lipid Lowering Study
While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a glucose analog, its signal in the vasculature…
- Conditions
- Hypercholesterolemia, Hypercholesterolemia, Familial, Atherosclerosis, Carotid Artery Plaque
- Trial name
- PIILL (NCT04073797)
- Testing
- Inclisiran, 68Ga-DOTATATE PET-MRI, Colchicine
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Cambridge
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lipid Lowering, Vascular Inflammation
Vascular Inflammation and Cholesterol Lowering Therapy
This study aim to detect change in vascular inflammation following intense lipid lowering therapy
- Trial name
- NCT02941016
- Testing
- Evolocumab or Alirocumab
- Where
- Denmark
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Dyslipidemias, Cardiovascular Diseases
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial…
- Conditions
- Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
- Trial name
- NCT05488431
- Testing
- Bempedoic acid
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- Priscilla Hsue, MD
Coronary Heart Disease (CHD)
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be…
- Trial name
- REALISTIC (NCT06936111)
- Testing
- Assessment of residual cholesterol and inflammatory risk factors
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shanghai Zhongshan Hospital
Hypertension, Dyslipidemias
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach.
- Conditions
- Hypertension, Dyslipidemias, Inflammatory Response, Chronic Inflammation
- Trial name
- MRDLT (NCT06622304)
- Where
- China
- Volunteers
- 250,736 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Hypercholesterolemia, Inflammation
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients
The effects of a nutraceutical combination (NC) containing low-dose monacolin K and berberine on lipid profile, proprotein convertase subtilisin/kexin type 9 (PCSK9), subclinical inflammation and arterial stiffness were…
- Conditions
- Hypercholesterolemia, Inflammation, Atherosclerosis
- Trial name
- NU-TRY(HIV) (NCT03470376)
- Testing
- Nutraceutical combination (NC), No nutraceutical combination (noNC)
- Volunteers
- 26 people
- Sponsor
- University Of Perugia
Atherosclerosis, Inflammation
Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging
The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.
- Trial name
- NCT00920101
- Testing
- Atorvastatin, Lifestyle counseling
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- National Defense Medical College, Japan
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible.
- Conditions
- Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
- Trial name
- NCT06096909
- Testing
- Tafolecimab, Cholesterol Absorption Inhibitor, Statin
- Where
- 2 sites in China
- Volunteers
- 3,684 people
- Sponsor
- China National Center for Cardiovascular Diseases